SCHEMBL3102807

SCHEMBL3102807

NCc1c(-c2ccc(F)cc2F)ncn1Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.41
P2RX7 Q99572 1/20 0.41
ROCK2 O75116 2/20 0.39
ROCK1 Q13464 2/20 0.39
TACR1 P25103 2/20 0.38
MAOB P27338 1/20 0.38
MAPT P10636 3/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
ICMT O60725 1/20 0.38
SLC29A1 Q99808 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
KCNH2 Q12809 1/20 0.37
ATM Q13315 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605740 0.90 P2RX7 (0.46) TAAR1P2RX7ROCK2ROCK1TACR1
SCHEMBL3096387 0.89 CDK9 (0.43) TAAR1ROCK2ROCK1
SCHEMBL3103140 0.85 DPP4 (0.40)
SCHEMBL3096357 0.83 DPP4 (0.41) POLB
SCHEMBL3088312 0.82 DPP4 (0.48) TAAR1P2RX7ROCK2ROCK1MAPT
SCHEMBL3088784 0.82 HPGD (0.43) TAAR1P2RX7ROCK2ROCK1MAOB
SCHEMBL3096481 0.81 PKM (0.42) P2RX7KDM4EGRIN1GRIN2B
SCHEMBL3096527 0.78 DPP4 (0.41) KDM4ESLC29A1
SCHEMBL3595937 0.78 CDK9 (0.46)
SCHEMBL3087715 0.78 DPP4 (0.39) MAOBMAPTKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728146-B2 Enzyme inhibitors PROBIODRUG AG (DE) 2010-06-01 US claimed
US-20100234397-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2010-09-16 US disclosed
US-20100234397-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2010-09-16 US disclosed
US-20100234397-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2010-09-16 US disclosed
US-7728146-B2 Enzyme inhibitors PROBIODRUG AG (DE) 2010-06-01 US disclosed
US-7728146-B2 Enzyme inhibitors PROBIODRUG AG (DE) 2010-06-01 US disclosed
US-20070244177-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 US disclosed
US-20070244177-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 US disclosed
WO-2007116092-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244177-A1 ENZYME INHIBITORS ACHE, BACE1, MAOA TAAR1 528/4885P2RX7 2321/4885ROCK2 2022/4885
US-20100234397-A1 ENZYME INHIBITORS ACHE, MAOA, BACE1 TAAR1 692/4885P2RX7 2025/4885ROCK2 2077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.